Aethlon Medical Inc
NASDAQ:AEMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aethlon Medical Inc
NASDAQ:AEMD
|
US |
|
Columbia Sportswear Co
NASDAQ:COLM
|
US |
|
Yankuang Energy Group Co Ltd
SSE:600188
|
CN |
|
K
|
Ksfinance Group JSC
VN:KSF
|
VN |
|
DATA MODUL Produktion und Vertrieb von elektronischen Systemen AG
XETRA:DAM
|
DE |
|
C
|
Covivio Hotels SCA
LSE:0IS8
|
FR |
|
Guizhou Zhenhua E-chem Inc
SSE:688707
|
CN |
|
Dainichi Co Ltd
TSE:5951
|
JP |
|
F
|
Franco-Nevada Corp
NYSE:FNV
|
CA |
|
Keiwa Inc
TSE:4251
|
JP |
|
M
|
MYP Ltd
SGX:F86
|
SG |
|
Neste Oyj
OMXH:NESTE
|
FI |
|
A
|
AMJ Land Holdings Ltd
NSE:AMJLAND
|
IN |
|
Fluor Corp
NYSE:FLR
|
US |
|
Cambridge Nutritional Sciences PLC
LSE:CNSL
|
UK |
|
Nisshin Seifun Group Inc
TSE:2002
|
JP |
Aethlon Medical Inc
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.
Oncology Trial Progress: Aethlon advanced to the second cohort of its Australian oncology trial, with two of three participants now treated and the third scheduled for late February.
Safety Review Timeline: Safety data from Cohort 2 will be submitted to the Data Safety Monitoring Board by late March, with a decision expected within a day on whether to proceed to Cohort 3.
Expanded Patient Pool: Recent enrollment initiatives have created a queue of potential participants for the next trial cohort, expected to accelerate study enrollment.
Cost Control: The company continues to emphasize disciplined spending, with year-to-date operating expenses down 27% from last year despite higher quarterly costs.
SLAMB System Collaboration: Work is underway to test Hemopurifier compatibility with a more flexible, less invasive blood pump system, which could broaden future clinical use but will not impact current trials.
Focus on Australia: Management confirmed no plans to resume clinical activity in India and remains focused on completing the Australian trial.
